Husband Wife

Join experts as they discuss the treatment and challenges of myeloproliferative neoplasms.

Learn the answers to important questions, such as:

  • What are myeloproliferative neoplasms (MPN)?
  • What are the tests for MPN?
  • What are the treatment options?

Two chances to attend!

 

Tuesday, May 1, 2018 · 6:00 – 7:15 PM ET

 

Saturday, May 5, 2018 · 11:00 AM – 12:15 PM ET

 

Each webinar will last approximately 1 hour and 15 minutes, including a Question & Answer session.

 

Download the MPN Webinar Flyer

 

Agenda:

  • Introduction
  • Expert Discussion of MPN
  • Question & Answer Session

Presenters:

Aaron T. Gerds, MD, MS
Chair, NCCN Guidelines® Panel for MPN
Case Comprehensive Cancer Center/Cleveland Clinic Taussig Cancer Institute

Jaclyn M. Mau, RN
Nurse, Care Coordinator
Case Comprehensive Cancer Center/Cleveland Clinic Taussig Cancer Institute

David Ricci
Board Member and Patient Advocate
MPN Research Foundation

Fee Information:

Webinars are FREE to attend. Also, all registrants may request a free copy of the NCCN Guidelines for Patients®: MPN during registration. The NCCN Guidelines for Patients are a patient-friendly version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). They are a good starting point to learn the best options for a type of cancer.

Intended Audience:

This event is designed for people with MPN, their caregivers, and their families.

Supporters:

This activity is supported through the NCCN Foundation, by a contribution from our industry supporter Incyte Corporation. NCCN independently develops and distributes the NCCN Guidelines for Patients. Our industry supporters do not participate in the development of the NCCN Guidelines for Patients and are not responsible for the content and recommendations contained therein.

This activity is supported and endorsed by a contribution from:
MPN RESEARCH FOUNDATION
(MPNResearchFoundation.org)

This activity is endorsed by:
MPN CANCER CONNECTION
MPN EDUCATION FOUNDATION
LEUKEMIA & LYMPHOMA SOCIETY